Key points from article :
Hanall Biopharma and Daewoong Pharmaceutical, both South Korean pharma companies, have invested in Vincere Biosciences, a longevity biotech firm.
Vincere Biosciences specializes in mitophagy-based therapeutics for neurodegenerative and other age-related diseases.
This strategic investment aims to boost research and development activities for Parkinson’s disease treatment.
While the size of the investment was not disclosed, the funds will be used for discovery of novel drug candidates, preclinical and clinical studies, and regulatory approval pursuits.
The collaboration seeks to leverage each company's specific knowledge and resources to accelerate the development of innovative treatments for Parkinson's disease.
HanAll Biopharma sees potential for collaborations with Vincere's AI platform to evolve their approach to drug development.
Parkinson’s disease, a neurodegenerative disorder with few therapeutic options, affects millions worldwide, hence the urgent need for novel treatments.
The CEOs of the three companies have expressed their commitment and optimism towards this collaboration for the advancement of Parkinson's treatments.
